

Correction

Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer**Mariya Shapovalova¹, Julia Davydova², Christine Henzler³, Mark Daniel⁴, Scott M. Dehm³, Christopher A. Warlick⁵ and Aaron M. LeBeau¹**¹Department of Pharmacology, University of Minnesota, Minneapolis 55455, MN, USA²Department of Surgery, University of Minnesota, Minneapolis 55455, MN, USA³Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455, MN, USA⁴Department of Microbiology and Immunology, University of Minnesota, Minneapolis 55455, MN, USA⁵Department of Urology, University of Minnesota, Minneapolis 55455, MN, USA**Published:** August 06, 2019**Copyright:** Shapovalova et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has been corrected:** The proper Grant Support information is shown below:**GRANT SUPPORT**

This research was supported by a Department of Defense Prostate Cancer Research Program Early Investigator Research Award – Predoctoral (MS), Prostate Cancer Foundation Young Investigator Award (AML), Randy Shaver Foundation Research Award (AML), Paul Calabresi NCI K12 Award through Mayo Clinic (AML) and an American Cancer Society Institutional Research Grant (AML).

Original article: Oncotarget. 2018; 9:36693–36704. <https://doi.org/10.18632/oncotarget.26401>